NO885389L - Fremgangsmaate for fremstilling av immobilisert interleukin 2, og interleukin 2 inneholdende en carboxylterminal forlengelse. - Google Patents

Fremgangsmaate for fremstilling av immobilisert interleukin 2, og interleukin 2 inneholdende en carboxylterminal forlengelse.

Info

Publication number
NO885389L
NO885389L NO88885389A NO885389A NO885389L NO 885389 L NO885389 L NO 885389L NO 88885389 A NO88885389 A NO 88885389A NO 885389 A NO885389 A NO 885389A NO 885389 L NO885389 L NO 885389L
Authority
NO
Norway
Prior art keywords
polypeptide
cells
mixture according
lysine
extension
Prior art date
Application number
NO88885389A
Other languages
English (en)
Norwegian (no)
Other versions
NO885389D0 (no
Inventor
Yuan Lin De Vries
Richard John Robb
Paul Simon
Charles Thayer White
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of NO885389D0 publication Critical patent/NO885389D0/no
Publication of NO885389L publication Critical patent/NO885389L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO88885389A 1987-12-04 1988-12-02 Fremgangsmaate for fremstilling av immobilisert interleukin 2, og interleukin 2 inneholdende en carboxylterminal forlengelse. NO885389L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12893187A 1987-12-04 1987-12-04

Publications (2)

Publication Number Publication Date
NO885389D0 NO885389D0 (no) 1988-12-02
NO885389L true NO885389L (no) 1989-06-05

Family

ID=22437677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO88885389A NO885389L (no) 1987-12-04 1988-12-02 Fremgangsmaate for fremstilling av immobilisert interleukin 2, og interleukin 2 inneholdende en carboxylterminal forlengelse.

Country Status (11)

Country Link
EP (1) EP0319012A3 (fr)
JP (1) JPH02300A (fr)
KR (1) KR890009978A (fr)
AU (1) AU2635088A (fr)
DK (1) DK673788A (fr)
FI (1) FI885628L (fr)
HU (1) HUT50506A (fr)
IL (1) IL88565A0 (fr)
NO (1) NO885389L (fr)
PT (1) PT89121A (fr)
ZA (1) ZA888978B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229272A (en) * 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
EP0460101A4 (en) * 1989-02-24 1992-04-15 Immunotherapeutics, Inc. Immobilized cytokines
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6955915B2 (en) 1989-06-07 2005-10-18 Affymetrix, Inc. Apparatus comprising polymers
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US6919211B1 (en) 1989-06-07 2005-07-19 Affymetrix, Inc. Polypeptide arrays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
EP0406857B1 (fr) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Protéines et leur production
FR2653020B1 (fr) * 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
WO1992000762A1 (fr) * 1990-07-05 1992-01-23 Akzo N.V. Conjugues de toxine destines a des recepteurs
FR2666898A1 (fr) * 1990-09-18 1992-03-20 Toledano Jacques Dispositif et procede de dosage rapide de recepteurs membranaires ou de leurs ligands.
US6072039A (en) * 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
US5635597A (en) * 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
FR2764988B1 (fr) * 1997-06-20 1999-07-23 Bio Merieux Compose conjugue, reactif et kit le contenant, et utilisations dans un procede de fixation d'un materiel biologique
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
CA2391080A1 (fr) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Formes d'erythropoietine dotees de proprietes ameliorees
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (fr) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reduction de l'immunogenicite de proteines de fusion
EP1383785B1 (fr) 2001-05-03 2011-03-16 Merck Patent GmbH Anticorps recombine a specificite tumorale et utilisation correspondante
JP4225196B2 (ja) 2001-07-03 2009-02-18 株式会社ジェイ・エム・エス 簡便な制御手段を有する血液透析装置
FR2832508A1 (fr) * 2001-11-21 2003-05-23 Bio Merieux Procede d'obtention d'une phase de capture et d'une phase de detection d'un materiel biologique cible et utilisation dans des tests elisa
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
WO2004055056A1 (fr) 2002-12-17 2004-07-01 Merck Patent Gmbh Forme humanisee de l'anticorps de souris 14.18 (h14.18) se liant au gd2 et fusion de celle-ci avec il-2
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
CA2555714C (fr) 2004-02-26 2013-12-03 Immunovative Therapies, Ltd. Procedes de preparation de lymphocytes t pour therapie cellulaire
CN100391726C (zh) * 2006-04-28 2008-06-04 江阴市万事达液压机械有限公司 缸体破碎机
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
WO2012151266A1 (fr) 2011-05-03 2012-11-08 Michael Har-Noy Procédés de manipulation de médicaments biologiques contenant des cellules vivantes
BR112013028285A2 (pt) 2011-05-03 2017-01-10 Immunovative Therapies Ltd indução de il-12 usando imunoterapia
AU2019301697A1 (en) * 2018-07-13 2021-01-07 Il-2Rx, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (fr) * 1983-08-10 1985-02-28 Amgen Expression microbienne de l'interleukine ii
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide

Also Published As

Publication number Publication date
KR890009978A (ko) 1989-08-05
FI885628A7 (fi) 1989-06-05
HUT50506A (en) 1990-02-28
NO885389D0 (no) 1988-12-02
IL88565A0 (en) 1989-07-31
FI885628A0 (fi) 1988-12-02
PT89121A (pt) 1989-12-29
EP0319012A3 (fr) 1990-05-16
FI885628L (fi) 1989-06-05
DK673788D0 (da) 1988-12-02
JPH02300A (ja) 1990-01-05
DK673788A (da) 1989-06-05
EP0319012A2 (fr) 1989-06-07
AU2635088A (en) 1989-06-08
ZA888978B (en) 1990-07-25

Similar Documents

Publication Publication Date Title
NO885389L (no) Fremgangsmaate for fremstilling av immobilisert interleukin 2, og interleukin 2 inneholdende en carboxylterminal forlengelse.
AU2001275246B2 (en) T cell receptor fusions and conjugates and methods of use thereof
KR100453314B1 (ko) Cd40l 돌연변이 단백질
CN112759641B (zh) 一种识别Kras G12V的高亲和力TCR
JP2001503266A (ja) 環状に並べ替えたエリスロポイエチン受容体アゴニスト
CA2239522A1 (fr) Proteine hybride a interferon-.alpha. et fragment fc d'immunoglobuline a liaison assuree par peptide non immunogene
AU2001275246A1 (en) T cell receptor fusions and conjugates and methods of use thereof
Kiyokawa et al. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells
US5217881A (en) Hyperglycosylated cytokine conjugates
JPH0763378B2 (ja) ＴＧＦ−βをコードしているＤＮＡ
US5932471A (en) DNA encoding chimeric toxin
CN111662374B (zh) 一种识别afp抗原的高亲和力tcr
CZ292689B6 (cs) Rekombinantní lektin z jmelí
CN107223133B (zh) 一种可溶的异质二聚t细胞受体及其制法和应用
CN113667004B (zh) 一种白介素2突变体
CN106432475B (zh) 高亲和力ny-eso t细胞受体
CN112409474B (zh) 一种识别ssx2抗原的高亲和力tcr
CN112442119B (zh) 一种识别ssx2的高亲和力t细胞受体
WO2023179768A1 (fr) Tcr à haute affinité pour identifier un antigène mage-a4, séquence et utilisation de celui-ci
WO2023221959A1 (fr) Récepteurs de lymphocytes t à haute affinité pour la reconnaissance de mage et leur utilisation
CN117659163A (zh) 一种识别afp的高亲和力t细胞受体及其应用
CN115746124A (zh) TGFβRII突变体及其应用
WO1991019745A1 (fr) Toxines chimeriques a geometrie inter-domaine amelioree
CN112480262B (zh) 一种融合蛋白及其制备与应用
CN105985444B (zh) 一种嵌合抗原受体、以及快速构建嵌合抗原受体的方法及应用